San Francisco, CA—The results of a phase 1b study of the combination of venetoclax plus rituximab (Rituxan) showed encouraging safety and excellent activity in patients with chronic lymphocytic leukemia (CLL). Venetoclax will move on to a phase 3 trial comparing venetoclax plus rituximab versus bendamustine (Treanda) plus ri­tuximab in patients with previously treated CLL. The drug is also being studied in acute myeloid leukemia (AML).
San Francisco, CA—Multiple myeloma is not a single disease entity but has genomic complexity and frequent intraclonal heterogeneity of myeloma cells. This realization, together with the availability of a number of new treatment possibilities, has underscored a need for better disease prognostication and monitoring tools, said Jesús San Miguel, MD, PhD, Professor of Hematology, and Director of Clinical and Translational Medicine, Clínica Universidad de Navarra, Pamplona, Spain, in delivering the Ham-Wasserman Lecture at the 2014 American Society of Hematology meeting.
San Francisco, CA—The checkpoint inhibitors—the anti–CTLA-4 agent ipi­limumab (Yervoy) and the PD-1 blockers nivolumab (Opdivo) and pembrolizumab (Keytruda)—have shown promise in multiple solid tumors and are showing hints of activity in hematologic malignancies as well. But based on early research, their use in hematology may be more limited.
San Francisco, CA—Most first-line therapies for myelodysplastic syndromes (MDS) fail, and this failure represents a greater financial burden to patients than was previously estimated by Medicare, according to Christopher R. Cogle, MD, Associate Professor of Medicine, University of Florida, Gainesville, and colleagues at the Cleveland Clinic in a poster presented at the 2014 American Society of Hematology meeting.
San Francisco, CA—At its 2014 meeting, the American Society of Hematology (ASH) released its second list of 5 common tests, treatments, and procedures to avoid in routine care.
San Francisco, CA—Genetic analysis reveals multiple drivers of pancreatic cancer. During a keynote address at the 2015 ASCO Gastrointestinal Cancers Symposium, Sean Grimmond, PhD, BSc, Chair of Medical Genomics, Institute of Cancer Sciences, University of Glasgow, Scotland, discussed the genetic characterization of pancreatic cancer, and how the current landscape may be used to target driver genes for drug development.
San Francisco, CA—Neal J. Meropol, MD, of the University Hospitals Seidman Cancer Center, and Case Western Reserve University, Cleveland, OH, has long advocated against unnecessary treatment and testing of patients with cancer. At the 2015 Gastrointestinal Cancers Symposium, Dr Meropol outlined his reasons why clinicians should not bend to pressure to routinely test all tumors.
Although less common than other skin cancers, melanoma is the most dangerous form of skin cancer. According to data collected between 2004 and 2010, the 5-year relative survival rate for Americans with distant melanoma is only 16% for all ages, races, and sexes. The National Cancer Institute estimated that there were 76,100 new cases of skin melanoma in 2014, and more than 9700 patients died from this disease during the same period.
A novel gene panel is showing promise for determining which treatment-naïve patients with prostate cancer could benefit from intensified treatment. A new study indicates that a 100-gene-loci panel can identify which patients with prostate cancer are most likely to fail treatment within 18 months, with a multivariable analysis yielding a hazard ratio of 2.9 for relapse.
Page 3 of 3
Results 21 - 29 of 29
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology